Published :
Tables : 49
Figures : 44
Category : Healthcare
No. of Pages : 226
Report Code : HC-U3453
Ophthalmic Drugs Market is poised to register a CAGR of 6.4% during the forecast period 2022 to 2028. Ophthalmic medications are formulations used to treat eye illnesses such as cataract, glaucoma, colour blindness, diabetic macular edoema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD). The rise in the elderly population, the prevalence of eye diseases such as glaucoma, cataracts, and macular degeneration, the surge in ophthalmic drug demand, and the increase in investment in research and development activities by various healthcare companies are the key factors driving the growth of the global ophthalmic drugs market. The growth in ophthalmic drug demand, greater healthcare awareness to lower the risk of eye problems, and government initiatives to study and create new combinations of ophthalmic pharmaceuticals are also driving the market. The retinal disease segment dominated the global ophthalmic drugs market by type of indication and is expected to maintain this trend during the forecast period, owing to the rise in the geriatric population, the prevalence of macular degeneration, and the surge in sales of ophthalmic drugs for the treatment of retinal disease. However, the glaucoma segment is expected to grow significantly throughout the forecast period due to rising glaucoma prevalence, rising demand for ophthalmic medications, and increased awareness of glaucoma prevention and treatment. North America accounted for a significant portion of the global market for ophthalmic drugs and is expected to maintain its leadership during the forecast period due to the rising prevalence of the elderly population, the rise in the prevalence of eye disease, and government initiatives for eye health. FutureWise Market Research has instantiated a report that provides an intricate analysis of Ophthalmic Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Ophthalmic Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Ophthalmic Drugs Market: • Aerie Pharmaceuticals, Inc. • Allergan • Valeant Pharmaceuticals International, Inc. • Bayer AG • Genentech, Inc. (F. Hoffmann-La Roche Ltd.) • Novartis AG • Pfizer Inc. • Regeneron Pharmaceuticals, Inc. • Santen Pharmaceutical Co., Ltd. • Actavis Generics (Teva Pharmaceutical Industries Ltd.) (Note: The list of the major players will be updated with the latest market scenario and trends) Ophthalmic Drugs Market Segmentation: By Product Type • Prescription Drugs • OTC Drugs By Therapeutic Class • Anti-inflammatory Drugs o NSAIDs o Steroids • Anti-infective Drugs o Anti-fungal Drugs o Anti-bacterial Drugs o Others • Anti-glaucoma Drugs o Alpha Agonist o Beta Blockers o Prostaglandin Analogs o Combined Medication o Others • Anti-allergy Drugs o Anti-VEGF Agents o Others By Disease Indication • Dry Eye • Glaucoma • Infection/ Inflammation • Retinal Disorders o Wet AMD o Dry AMD o Diabetic Retinopathy o Others • Allergy • Uveitis • Others By Distribution Channel • Hospital Pharmacies • Online Pharmacies • Independent Pharmacies & Drug Stores By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Ophthalmic Drugs Market Sample Video: Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Ophthalmic Drugs Market By Product Type, By Therapeutic Class, By Disease Indication, Distribution Channel and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Ophthalmic medications are formulations used to treat eye illnesses such as cataract, glaucoma, colour blindness, diabetic macular edoema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD). The rise in the elderly population, the prevalence of eye diseases such as glaucoma, cataracts, and macular degeneration, the surge in ophthalmic drug demand, and the increase in investment in research and development activities by various healthcare companies are the key factors driving the growth of the global ophthalmic drugs market.
The growth in ophthalmic drug demand, greater healthcare awareness to lower the risk of eye problems, and government initiatives to study and create new combinations of ophthalmic pharmaceuticals are also driving the market. The retinal disease segment dominated the global ophthalmic drugs market by type of indication and is expected to maintain this trend during the forecast period, owing to the rise in the geriatric population, the prevalence of macular degeneration, and the surge in sales of ophthalmic drugs for the treatment of retinal disease. However, the glaucoma segment is expected to grow significantly throughout the forecast period due to rising glaucoma prevalence, rising demand for ophthalmic medications, and increased awareness of glaucoma prevention and treatment.
North America accounted for a significant portion of the global market for ophthalmic drugs and is expected to maintain its leadership during the forecast period due to the rising prevalence of the elderly population, the rise in the prevalence of eye disease, and government initiatives for eye health.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Ophthalmic Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Ophthalmic Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Ophthalmic Drugs Market: • Aerie Pharmaceuticals, Inc. • Allergan • Valeant Pharmaceuticals International, Inc. • Bayer AG • Genentech, Inc. (F. Hoffmann-La Roche Ltd.) • Novartis AG • Pfizer Inc. • Regeneron Pharmaceuticals, Inc. • Santen Pharmaceutical Co., Ltd. • Actavis Generics (Teva Pharmaceutical Industries Ltd.) (Note: The list of the major players will be updated with the latest market scenario and trends)
Ophthalmic Drugs Market Segmentation: By Product Type • Prescription Drugs • OTC Drugs By Therapeutic Class • Anti-inflammatory Drugs o NSAIDs o Steroids • Anti-infective Drugs o Anti-fungal Drugs o Anti-bacterial Drugs o Others • Anti-glaucoma Drugs o Alpha Agonist o Beta Blockers o Prostaglandin Analogs o Combined Medication o Others • Anti-allergy Drugs o Anti-VEGF Agents o Others By Disease Indication • Dry Eye • Glaucoma • Infection/ Inflammation • Retinal Disorders o Wet AMD o Dry AMD o Diabetic Retinopathy o Others • Allergy • Uveitis • Others By Distribution Channel • Hospital Pharmacies • Online Pharmacies • Independent Pharmacies & Drug Stores By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Ophthalmic Drugs Market Sample Video:
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Ophthalmic Drugs Market By Product Type, By Therapeutic Class, By Disease Indication, Distribution Channel and By Region. • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Ophthalmic Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Ophthalmic Drugs Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Ophthalmic Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Ophthalmic Drugs Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Prescription Drugs 7.2. OTC Drugs 8. Global Ophthalmic Drugs Market, By Therapeutic Class Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Anti-inflammatory Drugs 8.1.1. NSAIDs 8.1.2. Steroids 8.2. Anti-infective Drugs 8.2.1. Anti-fungal Drugs 8.2.2. Anti-bacterial Drugs 8.2.3. Others 8.3. Anti-glaucoma Drugs 8.3.1. Alpha Agonist 8.3.2. Beta Blockers 8.3.3. Prostaglandin Analogs 8.3.4. Combined Medication 8.3.5. Others 8.4. Anti-allergy Drugs 8.4.1. Anti-VEGF Agents 8.4.2. Others 9. Global Ophthalmic Drugs Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Dry Eye 9.2. Glaucoma 9.3. Infection/ Inflammation 9.4. Retinal Disorders 9.4.1. Wet AMD 9.4.2. Dry AMD 9.4.3. Diabetic Retinopathy 9.4.4. Others 9.5. Allergy 9.6. Uveitis 9.7. Others 10. Global Ophthalmic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hospital Pharmacies 10.2. Online Pharmacies 10.3. Independent Pharmacies & Drug Stores 11. North America Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Aerie Pharmaceuticals, Inc. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Allergan 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Valeant Pharmaceuticals International, Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Bayer AG 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5 Genentech, Inc. (F. Hoffmann-La Roche Ltd.) 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6 Novartis AG 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Pfizer Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Regeneron Pharmaceuticals, Inc. 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Santen Pharmaceutical Co., Ltd. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Actavis Generics (Teva Pharmaceutical Industries Ltd.) 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Global Ophthalmic Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Ophthalmic Drugs Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Ophthalmic Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Ophthalmic Drugs Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Prescription Drugs 7.2. OTC Drugs
8. Global Ophthalmic Drugs Market, By Therapeutic Class Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Anti-inflammatory Drugs 8.1.1. NSAIDs 8.1.2. Steroids 8.2. Anti-infective Drugs 8.2.1. Anti-fungal Drugs 8.2.2. Anti-bacterial Drugs 8.2.3. Others 8.3. Anti-glaucoma Drugs 8.3.1. Alpha Agonist 8.3.2. Beta Blockers 8.3.3. Prostaglandin Analogs 8.3.4. Combined Medication 8.3.5. Others 8.4. Anti-allergy Drugs 8.4.1. Anti-VEGF Agents 8.4.2. Others
9. Global Ophthalmic Drugs Market, By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Dry Eye 9.2. Glaucoma 9.3. Infection/ Inflammation 9.4. Retinal Disorders 9.4.1. Wet AMD 9.4.2. Dry AMD 9.4.3. Diabetic Retinopathy 9.4.4. Others 9.5. Allergy 9.6. Uveitis 9.7. Others
10. Global Ophthalmic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Hospital Pharmacies 10.2. Online Pharmacies 10.3. Independent Pharmacies & Drug Stores
11. North America Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific Ophthalmic Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Aerie Pharmaceuticals, Inc. 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Allergan 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Valeant Pharmaceuticals International, Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Bayer AG 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5 Genentech, Inc. (F. Hoffmann-La Roche Ltd.) 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6 Novartis AG 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Pfizer Inc. 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Regeneron Pharmaceuticals, Inc. 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Santen Pharmaceutical Co., Ltd. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Actavis Generics (Teva Pharmaceutical Industries Ltd.) 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics